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Strengths and limitations of this study
 ► The main strengths include the nationwide 
population- based design in the setting of a uniform-
ly organised healthcare system where accurate link-
age between national medical registries is possible.
 ► The study was based on prospectively collected data 
from registries, which are considered to have a high 
validity.
 ► Analyses were based on the underlying cause of 
death of well- defined chronic diseases in order to 
avoid introducing misclassification, since it remains 
difficult to determine and differentiate between un-
derlying and immediate cause of death.
 ► Register- based data give some limitations to the 
study as these cannot provide detailed information 
on patients’ disease status, palliative needs and 
preferences in order to differentiate whether non- 
cancer and cancer patients are hospitalised for 
comparable reasons.
AbStrACt
Objectives End- of- life hospitalisations may not be 
associated with improved quality of life. Studies indicate 
differences in end- of- life care for cancer and non- cancer 
patients; however, data on hospital utilisation are sparse. 
This study aimed to compare end- of- life hospitalisation 
and place of death among patients dying from cancer, 
heart failure or chronic obstructive pulmonary disease 
(COPD).
Design A nationwide register- based cohort study.
Setting Data on all in- hospital admissions obtained from 
nationwide Danish medical registries.
Participants All decedents dying from cancer, heart 
failure or COPD disease in Denmark between 2006 and 
2015.
Outcome measures Data on all in- hospital admissions 
within 6 months and 30 days before death as well as place 
of death. Comparisons were made according to cause of 
death while adjusting for age, sex, comorbidity, partner 
status and residential region.
results Among 154 235 decedents, the median total bed 
days in hospital within 6 months before death was 19 days 
for cancer patients, 10 days for patients with heart failure 
and 11 days for patients with COPD. Within 30 days before 
death, this was 9 days for cancer patients, and 6 days 
for patients with heart failure and COPD. Compared with 
cancer patients, the adjusted relative bed day use was 
0.65 (95% CI, 0.63 to 0.68) for heart failure patients and 
0.68 (95% CI, 0.66 to 0.69) for patients with COPD within 
6 months before death. Correspondingly, this was 0.65 
(95% CI, 0.63 to 0.68) and 0.70 (95% CI, 0.68 to 0.71) 
within 30 days before death.
Patients had almost the same risk of dying in hospital 
independently of death cause (46.2% to 56.0%).
Conclusion Patients with cancer, heart failure and COPD 
all spent considerable part of their end of life in hospital. 
Hospital use was highest among cancer patients; however, 
absolute differences were small.
IntrODuCtIOn
Most patients with chronic diseases prefer to 
remain at home as much as possible towards 
the end of life, and a high level of hospital 
care in the last months of life may, therefore, 
not be associated with improved quality of 
life.1–7 Nevertheless, terminally ill patients 
may spend considerable time in hospitals and 
often die there.2 8
Prior research indicate that end- of- life care 
to patients with non- cancer diagnoses may be 
sub- optimal compared with that of patients 
with cancer diagnoses, and that healthcare 
professionals are often better educated to 
identify the terminal phase and manage end- 
of- life care among cancer patients.9–11 Diffi-
culties in predicting illness trajectories for 
non- cancer patients approaching the end of 
life are likely to explain some of the difference 
in access to palliative care services between 
cancer and non- cancer patients.12–19 Thus, 
even though incurably ill non- cancer patients 
experience similar physical and psychosocial 
needs as cancer patients, they may receive 
fewer palliative care services and thereby 
more often experience hospitalisations in 
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the end of life.9 20–31 However, there is a paucity of large 
scale population- based studies comparing healthcare 
utilisation among terminally ill non- cancer and cancer 
patients and it is consequently difficult for healthcare 
professionals, administrators and health policy makers to 
address potential inequalities. More insight is warranted 
on care needs among end- of- life patients across different 
disease conditions in order to understand current illness 
trajectories and to ensure that healthcare systems are 
responsive and appropriately organised to meet palliative 
care needs.
We therefore compared hospitalisation patterns within 
the last 6 months and 30 days before death as well as place 
of death for all Danes who died of cancer with those who 
died of heart failure or chronic obstructive pulmonary 
disease (COPD). We also examined the trends according 
to calendar years of death in order to identify any 
temporal changes.
MethODS
Study design and setting
We conducted a nationwide follow- up study among all 
adult decedents in Denmark who died from cancer, heart 
failure or COPD from 1 January 2006 to 31 December 
2015. The study was based on individual- level linkage 
of national medical registries using the 10- digit unique 
personal civil registration number assigned to all Danish 
residents.32 33
The healthcare system in Denmark is tax- supported 
and provided to all residents, who thereby have equal 
access to healthcare, including access to public hospitals, 
hospices, general practitioners and specialists in palliative 
care. Private hospitals play a minor role in Denmark and 
only for elective surgical and diagnostic procedures. Only 
public hospitals are involved in acute medical and palli-
ative care.
In accordance with Danish law, non- interventional 
studies in Denmark do not require approval from ethics 
committees. The current study was approved by the 
Danish Data Protection Agency on 4 July 2014 (Central 
Denmark Region record number: 1-16-02-407-14).
Decedents
We used the Danish Register of Causes of Death to identify 
all decedents at the age of 18 years or older, who had been 
residents in Denmark for at least 6 months before death 
and registered with cancer (International Classification 
of Diseases, Tenth Revision (ICD-10) codes: DC00-14, 
DC15-26, DC30-39, DC40-41, DC43-44, DC50, DC51-58, 
DC60-63, DC64-68, DC69-72, DC73-75, DC76-80, DC81-
96), heart failure (ICD-10 codes: I11.9, I13.0, I13.2, I42.0, 
I42.6, I42.7, I42.9, I50.0, I50.1, I50.9) or COPD (ICD-10 
codes: J41-44, J47) as the underlying cause of death.
Independence between the three patient populations 
was ensured by excluding patients, who died of one of the 
three conditions while also having a history of one or both 
of the other conditions according to information from 
the Danish National Patient Registry (please see below 
for information on this registry). Hence, a patient with 
cancer as the underlying cause of death was excluded if 
he/she had one or more previous hospital contacts for 
COPD and/or heart failure.
The Danish Register of Causes of Death is a nationwide 
registry with data collection since 1970 with a complete-
ness of approximately 97%.34 Data are obtained from 
death certificates filled for every decedent and include 
civil registration number, date of death, manner of death 
and cause of death, both immediate and underlying, 
reported as a chain of one to four conditions that led to 
death. Causes of death are coded according to the Danish 
version of ICD.35
hospital admissions
We identified all hospital admissions, including public 
and private hospitals, within 6 months before death on 
all included patients using the Danish National Patient 
Registry. The Danish National Patient Registry was 
established in 1977, and since then it has been manda-
tory for all Danish hospitals to register information on 
hospital admissions, including dates of all admissions and 
discharges, patients’ discharge diagnoses, surgical proce-
dures and patients’ residence.36
Using the Danish National Patient Registry, we retrieved 
the following data on the study population: (1) the total 
number of bed days, (2) the total number bed days 
initiated by acute and elective admissions, (3) the total 
number of admissions and the corresponding number of 
days per admission and (4) the number and proportion 
of patients hospitalised on date of death.
In addition, we retrieved data on age at death, sex, 
comorbidity (assessed using the Charlson Comorbidity 
Index37 38 and residential region using the Danish National 
Patient Registry, and data regarding partner status using 
The Danish Civil Registration System for all patients.33 
We computed the Charlson Comorbitdity Index based on 
the entire hospitalisation history of each patient in the 10 
years leading up to death, including both admissions with 
overnight stay and outpatient visits. The weights of 19 
selected conditions were summed to a comorbidity score 
excluding the cause of death.37 38
Statistical methods
Median total bed days within 6 months and 30 days before 
death and the corresponding percentages of time spent 
in hospital were estimated for the three patient popula-
tions. In the same way, we estimated the median total bed 
days within 6 months and 30 days before death after acute 
and elective hospital admissions.
For each patient population, we computed the median 
number of hospital admissions and median days per 
hospital admission within 6 months and 30 days before 
death. We also computed the proportion of patients 
dying in hospital.
Finally, we estimated the relative total bed days, relative 
bed days after acute admission and elective admission, 
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Table 1 Characteristics of patients who died of cancer, heart failure or COPD in Denmark between 2006 and 2015
Patient characteristics
Died of cancer
(n=1 23 212)
Died of heart 
failure
(n=9758)
Died of COPD
(n=21 265)
Total
(n=1 54 235)
Age, years
  Median (Q1; Q3) 73.0 (64.3; 81.4) 86.7 (79.0; 91.8) 79.7 (72.5; 85.3) 75.0 (65.7; 83.1)
Sex, n (%)
  Female 59 645 (48.4) 5225 (53.6) 11 921 (56.1) 76 791 (49.8)
  Male 63 567 (51.6) 4533 (46.5) 9344 (43.9) 77 444 (50.2)
  Partner status, n (%)
  Living alone 57 671 (46.8) 7250 (74.3) 14 598 (68.7) 79 519 (51.6)
  Living with a partner 65 541 (53.2) 2503 (25.7) 6667 (31.4) 74 716 (48.4)
Geographical region of residence, n (%)
  North Denmark Region 13 776 (11.2) 1121 (11.5) 2671 (12.6) 17 568 (11.4)
  Central Denmark Region 26 623 (21.6) 1936 (19.8) 4624 (21.7) 33 183 (21.5)
  Region of Southern Denmark 27 690 (22.5) 2281 (23.4) 4829 (22.7) 34 800 (22.6)
  Capital Region 34 490 (28.0) 2885 (29.6) 5783 (27.2) 43 158 (28.0)
  Zealand Region 20 633 (16.8) 1535 (15.7) 3358 (15.8) 25 526 (16.6)
Admitted to hospital within 
6 months before death, n (%)
115 093 (93.4) 7359 (75.4) 17 387 (81.8) 139 839 (90.7)
Admitted to hospital within 30 days 
before death, n (%)
82 079 (66.6) 5447 (55.8) 13 624 (64.1) 101 150 (65.6)
Comorbidity, points*
  0 47 260 (38.4) 3902 (40.0) 11 307 (53.2) 62 469 (40.5)
  1 16 704 (13.6) 2491 (25.5) 5660 (26.6) 24 855 (16.1)
  2 to 3 15 290 (12.4) 2401 (24.6) 3384 (15.9) 21 075 (13.7)
  4+ 43 958 (35.7) 964 (9.9) 914 (4.3) 45 836 (29.7)
*Calculated according to Charlson Comorbidity Index, excluding underlying cause of death.
COPD, chronic obstructive pulmonary disease.
relative number of hospital admissions, relative length per 
admission and the relative risk of dying during hospital 
admission for patients who died of heart failure or COPD 
compared with patients who died of cancer. The relative 
estimates were adjusted for age, sex, comorbidity, partner 
status and residential region using linear regression 
analysis transformed by natural logarithm. Similarly, the 
adjusted relative risk of dying during hospital admission 
were estimated using multivariable binomial regression.
The statistical analyses were performed using Stata 
14.2 (StataCorp. 2015. Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP) on a secure remote 
server of Statistics Denmark.
Patient and public involvement
There were no patients or members of the public 
involved in the design, conduct, analyses or reporting of 
our research.
reSultS
We identified 154 235 patients who died of cancer 
(n=1 23 212), heart failure (n=9758) or COPD (n=21 265) 
between 2006 and 2015. Among these decedents, 90.7% 
were admitted to hospital at least once within the last 
6 months of life (398 983 admissions) (table 1).
bed day use
Among the decedents included in the study, the median 
total bed days in hospital within 6 months before death 
was 19 days for cancer patients, 10 days for heart failure 
patients and 11 days for COPD patients (table 2).
The median total bed days within the last 30 days before 
death was 9 days for cancer patients and 6 days for heart 
failure and COPD patients (table 2).
The median total bed days within 6 months before 
death decreased from 2006 to 2015 for cancer patients, 
whereas it remained unchanged for heart failure and 
COPD patients (figure 1). The number of total bed days 
within 30 days as well as the number of hospitals admis-
sions and length of stay per admission within 6 months 
and 30 days before death remained stable for all patient 
populations during the study period (data not shown).
The adjusted relative bed days within 6 months before 
death was 0.65 (95% CI, 0.63 to 0.67) for heart failure 
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Table 2 Hospitalisation use according to underlying disease: total bed days in hospital, proportion of bed days, number of 
hospital admissions, length per admission and proportion of patients dying in hospital
Hospital admissions Died of cancer Died of heart failure Died of COPD Total
Total bed day use, days, median (Q1; Q3)
  6 months before death 19 (9; 34) 10 (4; 23) 11 (5; 23) 17 (8; 32)
  30 days before death 9 (4; 15) 6 (2; 11) 6 (2; 12) 8 (3; 15)
Proportion of bed days, %
  6 months before death 10.4 5.5 6 9.3
  30 days before death 30 20 20 26.7
Number of hospital admissions,
n (Q1; Q3)
  6 months before death 2 (1; 4) 1 (1; 2) 2 (1; 3) 2 (1; 4)
  30 days before death 1 (1; 2) 1 (1; 1) 1 (1; 1) 1 (1; 2)
Length of stay per hospital admission, days, median (Q1; Q3)
  6 months before death 4 (1; 10) 6 (2; 11) 5 (2; 10) 4 (1; 10)
  30 days before death 5 (2; 11) 5 (2; 10) 5 (2; 10) 5 (2; 11)
Proportion of patients dying in hospital, % 56 46.2 55.5 55.3
COPD, chronic obstructive pulmonary disease.
Figure 1 Total bed day use within 6 months before death 
according to cause of death and calendar year.
patients and 0.68 (95% CI, 0.66 to 0.69) for COPD 
patients when compared with cancer patients (table 3). 
Unadjusted results are available in online supplementary 
table 1. The adjusted relative bed days were relatively 
unchanged when restricting the analyses to the last 30 
days before death (table 3).
Within 6 months before death, acute admissions 
accounted for 76.0% of all hospital admissions of cancer 
patients, whereas this was 93.5% for heart failure patients 
and 96.0% for COPD patients. Correspondingly, within 
30 days before death, this was 84.3% for cancer patients, 
96.3% for heart failure patients and 97.9% for COPD 
patients.
Among patients acutely admitted to hospital within 
6 months before death, the median total bed days within 
this period was 16 days for cancer patients, 11 days for heart 
failure patients and 12 days for COPD patients. Within the 
last 30 days before death, the median total bed days initi-
ated by acute admission was 8 days for cancer patients and 
6 days for both heart failure and COPD patients.
Correspondingly, the median total bed days initiated 
by elective admission within 6 months before death was 5 
days for cancer patients, 4 days for heart failure patients 
and 3 days for COPD patients, and within 30 days before 
death, this was 6 days for cancer patients and 4 days for 
both heart failure and COPD patients.
The adjusted relative bed days initiated by acute and 
elective admission showed less difference between the 
three patient populations as for the total number of days 
in hospital, both within 6 months and 30 days before 
death.
number of hospital admissions and length per admission
Patients who died from cancer or COPD had a median 
of two hospital admissions within 6 months before death, 
whereas patients who died of heart failure had a median 
of one hospital admission within 6 months before death 
(table 2). Within the last 30 days leading up to death, all 
patient populations had a median of one hospital admis-
sion (table 2). The number of admissions did not vary 
systematically when stratified by calendar years of death 
(online supplementary table 2).
We observed variation in the number of admissions 
within 6 months before death in the adjusted estimates, 
comparing heart failure patients (0.84 (95% CI, 0.83 to 
0.85)) and COPD patients (0.85 (95% CI, 0.84 to 0.86)) 
with cancer patients (table 3). Less variation in the 
number of admissions was identified when restricting 
analyses to patients admitted to hospital within 30 days 
before death (heart failure patients: 0.95 (95% CI, 0.94 to 
0.96), COPD patients: 0.95 (95% CI, 0.95 to 0.96)).
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Table 3 Adjusted relative use of hospital for patients who died of heart failure or COPD when compared with patients with 
cancer
Hospital admissions Died of cancer Died of heart failure* Died of COPD*
Relative total bed day use (95% CI)
  6 months before death 1.0 (reference) 0.65 (0.63 to 0.67) 0.68 (0.66 to 0.69)
  30 days before death 1 0.65 (0.63 to 0.68) 0.70 (0.68 to 0.71)
Relative number of hospital admissions (95% CI)
  6 months before death 1 0.84 (0.83 to 0.85) 0.85 (0.84 to 0.86)
  30 days before death 1 0.95 (0.94 to 0.96) 0.95 (0.95 to 0.96)
Relative length of stay per hospital admission (95% CI)
  6 months before death 1 1.07 (1.04 to 1.10) 1.15 (1.13 to 1.17)
  30 days before death 1 0.75 (0.72 to 0.78) 0.82 (0.80 to 0.84)
Prevalence proportion ratio of in- hospital death (95% CI) 1 1.03 (1.00 to 1.06) 0.95 (0.93 to 0.97)
*Adjusted for age, sex, comorbidity, partner status and residential region.
COPD, chronic obstructive pulmonary disease.
Patients’ median length of stay per hospital admis-
sion within the last 6 months of life was 4 days for cancer 
patients, 6 days for heart failure patients and 5 days for 
COPD patients (table 2). Median length of stay within the 
last 30 days of life was 5 days for all patient populations. 
Limited differences between cancer and non- cancer 
patients were observed when adjusting for the covariates. 
For hospital admissions within 6 months before death, the 
adjusted relative median length per hospital admission 
was 1.07 (95% CI, 1.04 to 1.10) for heart failure patients 
and 1.15 (95% CI, 1.13 to 1.17) for COPD patients when 
compared with cancer patients (table 3). Correspond-
ingly, for hospital admissions within 30 days before death, 
the adjusted relative median length per hospital admission 
was 0.75 (95% CI, 0.72 to 0.78) for heart failure patients 
and 0.82 (95% CI, 0.80 to 0.84) for COPD patients when 
compared with cancer patients (table 3).
Place of death
The proportion of patients dying in hospital was 56.0% 
of cancer patients, 46.2% of heart failure patients and 
55.5% of COPD patients (table 2).
The adjusted relative risk of dying in hospital was 1.03 
(95% CI, 1.00 to 1.06) for heart failure patients and 0.95 
(95% CI, 0.93 to 0.97) for COPD patients when compared 
with cancer patients (table 3).
DISCuSSIOn
We found that hospitalisation near the end of life was 
common irrespective of the underlying disease, although 
the total number of bed days in hospital within 6 months 
before death has been reduced for all patients between 
2006 and 2015. Compared with patients dying of cancer, 
non- cancer patients had shorter total bed days but 
comparable length per hospital admission and number of 
hospital admissions within both the last 6 months and 30 
days before death. Still, there were no major differences 
in the risk of dying in hospital for cancer versus non- 
cancer patients.
The main strengths of our study include the nationwide 
population- based design in the setting of a uniformly 
organised healthcare system where accurate linkage 
between national medical registries is possible. The study 
was based on data from registries, which are considered 
to have a high validity.36
However, the limitations should also be taken into 
account. The method that we used to examine hospi-
talisations for patients at the end of life using a sample 
of decedents only, has been criticised, as it artificially 
removes the uncertainty of prognostication in patients at 
the end of life.39 Yet, it is a clinical challenge to determine 
when patients enter the terminal phase of life, wherefore 
a traditional follow- up study would be difficult. Our anal-
yses were based on the underlying cause of death of well- 
defined chronic diseases in order to avoid introducing 
misclassification, since it remains difficult to determine 
and differentiate between underlying and immediate 
cause of death. Validation of the Danish Register of 
Causes of Death is sparse and only performed for some 
diseases, leaving some uncertainty about classification of 
the causes of death; however, selection bias is unlikely.40 
In the Danish National Patient Registry, only few admis-
sions and discharges are not registered, which indicates 
low risk of information bias concerning patients’ end- of- 
life hospitalisations.36
Register- based data give some limitations to the study 
as these cannot provide detailed information on patients’ 
disease status, palliative needs and preferences in order 
to differentiate whether non- cancer and cancer patients 
are hospitalised for comparable reasons. There may also 
be residual confounding and confounding from unmea-
sured factors, since information on lifestyle factors, socio-
economic status, severity of illness and other factors was 
not available in the current study.
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Previous studies examining end- of- life care for deceased 
cancer patients have shown that hospitalisations near the 
end of life are very frequent across countries and health-
care systems.41 However, existing data directly comparing 
end- of- life care patterns for cancer and non- cancer 
patients are sparse, and the studies are small with a few 
exceptions.
A US study comparing end- of- life care patterns within 
6 months before death among COPD and lung cancer 
patients (n=1949) also found that COPD and lung cancer 
patients had a similar risk of dying in hospital.30 However, 
unlike our study, they found, that COPD patients had 
fewer hospital admissions compared with lung cancer 
patients, and that the total hospital bed days was similar 
for COPD and lung cancer patients. Since the sample 
population in the US study was smaller than in the current 
study and predominantly included elderly white men, this 
may explain some of the variation between the findings in 
the two studies.
Teno et al examined changes in site of death, place of 
care and healthcare transitions between 2000, 2005 and 
2009 among a 20% sample of Medicare beneficiaries, aged 
66 years and older.42 Improvements in care were observed 
over time for all patients; however, COPD patients were 
consistently more likely to die in acute care settings and 
received less hospice care compared with cancer patients. 
In contrast, no major difference in bed day use within 90 
days before death was observed.
Wachterman et al conducted a cross- sectional study 
in all 146 inpatient facilities within the Veteran Affairs 
health system.43 The study included 57 753 decedents, all 
of whom died in inpatients facilities. Patients with COPD 
and/or heart failure had a lower chance of receiving palli-
ative care consultations and a higher risk of dying in the 
intensive care unit compared with patients with cancer. 
Moreover, the chance of receiving excellent quality of 
end- of- life care as reported by the decedents' families was 
also lower for patients with COPD and/or heart failure.
Finally, Lastrucci et al recently reported a registry study 
from the Tuscany region in Italy where they compared 
indicators for quality of end- of- life care between patients 
with COPD or heart failure and cancer.44 For all indica-
tors, patients dying from COPD or heart failure came out 
worse, including a higher risk of dying in an acute care 
hospital and being hospitalised or admitted to the emer-
gency department and a lower chance of using hospice 
services in the last month of life compared with cancer 
patients.
Studies have suggested that variation in end- of- life 
care among patients with different underlying disease is 
caused by the perceived unpredictable illness trajecto-
ries of non- malignant chronic illnesses.12–19 Since early 
recognition of impending death is known to be crucial 
for optimal care for terminally ill patients, end- of- life 
care is challenging among non- cancer patients, whose 
illness trajectories tend to be less predictable compared 
with that of cancer patients.40 Therefore, we expected 
the current study to reveal that non- cancer patients spent 
more time in hospital compared with cancer patients, but 
this was not the case. One reason may be that improved 
cancer treatments are likely to have implications for the 
disease course, wherefore this may begin to resemble that 
of non- cancer patients.
Studies report that patients with non- cancer condi-
tions have equivalent or even greater symptom burden, 
compared with those with cancer.17 41 45 46 The slightly 
lower use of hospital among non- cancer patients found 
in the current study could therefore indicate that the 
symptom relief of non- cancer patients to a larger extent, 
as for cancer patients, were met in another setting (eg, by 
general practitioners). In fact, previous findings indicate 
that patients who receive home- based palliative care or 
palliative care from their general practitioner spend less 
time in hospital at the end of life.39 47–53 However, it may 
also indicate that the palliative needs of symptom relief 
among non- cancer patients are not acknowledged as 
such. In a recent study, we found, that patients dying from 
non- cancer conditions were twice as likely to be admitted 
to intensive care units at the end of life.54 This may indi-
cate that non- cancer patients are treated aggressively and 
maybe unnecessarily towards the end of life, although 
the current study showed that their overall bed day use 
was somewhat lower compared with cancer patients. Still, 
non- cancer patients were more likely than cancer patients 
to be acutely admitted to hospital, and when looking 
only at acute and elective admissions, the bed day use of 
cancer and non- cancer patients was almost the same. This 
may suggest that non- cancer and cancer patients are not 
admitted to hospital for completely comparable reasons. 
Yet, further efforts are needed in order to disentangle the 
mechanisms leading to admissions for different patient 
populations and to explore whether these could have 
been avoided.
Our findings of decrease in hospital bed day use between 
2006 and 2015 could be explained by the increasing 
number of outpatient treatments in the Danish health-
care system in general, replacing some hospital admis-
sions.55 Nevertheless, some of the decrease may also be 
explained by increased levels of out- of- hospital palliative 
care in Denmark during the period, where the specialised 
palliative care approach has advanced substantially over 
the past decade along with an increased focus on pallia-
tive care in the rest of the healthcare system.56
The current study does not allow us to determine 
whether the observed high levels of end- of- life hospi-
talisation are appropriate for cancer and non- cancer 
patients, nor whether it reflects unmet palliative needs, 
lack of communication about end- of- life preferences, 
or difficulties recognising patients having terminal 
prognosis. Nevertheless, the high levels of hospitalisa-
tion use and death at hospital warrants consideration 
of whether palliative needs are appropriately accommo-
dated. Furthermore, the findings question the common 
belief that inequality in palliative care exists among 
terminally ill patients with different underlying diag-
nosis. Still, more extensive information on end- of- life 
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care patterns will be required in order to clarify these 
important issues.
COnCluSIOn
Patients with cancer, heart failure and COPD, all spent a 
substantial part of their time at the end of life being hospi-
talised, and a high proportion of the patients continue to 
die in hospital settings. The use of hospitalisations was 
highest among cancer patients, although the absolute 
differences were small, and for all patient populations, it 
decreased between 2006 and 2015. Still, more insights in 
end- of- life care patterns are required in order to clarify 
the balance between patient needs and the care delivered 
by the healthcare system.
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